As technology gets better than ever, we're unlocking new medical discoveries with the potential to earn billions. However, it's important to not lose sight of what drove us towards these discoveries in the first place: the needs of the patients, and in the case of diseases such as Alzheimer's, their caregivers. Today, we're joined by Dr. Brandy Matthews on behalf of Eli Lilly, which is currently the largest pharmaceutical company in the world with a market cap of over $800 billion. Join us as Dr. Matthews talks us through the recent FDA approval of Alzheimer's drug Kisunla, learning from negative trials, and adopting a treatment approach centering patients and caregivers through the LillyDirect program.
See more of Lilly's work: www.lilly.com/
Dr. Brandy Matthews is the Vice President of Global and US Medical Affairs for Alzheimer's disease at Eli Lilly and Company. She has a background in clinical neurology with a medical degree from the Indiana University School of Medicine and a completed neurology residency at the Mayo Clinic.